Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, PR positive status confers therapeutic sensitivity to Letrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved letrozole as a treatment option for the treatment of patients who are women with natural or artificially induced postmenopausal endocrine status with advanced breast cancer after relapse or disease progression. This therapy regimen lists hormone receptor-negative status as an exclusion criteria.
This statement is based on a regulatory approval from the Health Service Executive:
Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.